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Supplementary data for: 
Abnormal electrophysiological testing associates with future incidental significant 
arrhythmia in Scleroderma  
 
METHODS 
Signal averaged electrocardiogram (ECG) (SAE) 
An abnormal SAE was defined as the presence of two of the following criteria: total 
QRS S┌ヴ;デｷﾗﾐ ふaｷﾉデWヴWSぶ дヱヱヴﾏゲが S┌ヴ;デｷﾗﾐ ﾗa high frequency low amplitude (HFLA) 
ゲｷｪﾐ;ﾉゲ ﾉWゲゲ デｴ;ﾐ ヴヰ┌V дンΓﾏゲが ヴﾗﾗデ ﾏW;ﾐ ゲケ┌;ヴWS ふRMSぶ ┗ﾗﾉデ;ｪW ｷﾐ デWヴﾏｷﾐ;ﾉ ヴヰﾏゲ 
<20uV [1].  
Autonomic testing 
This was determined using ECG monitoring and performed in the electrophysiology 
lab before implantation of the implantable loop recorder (ILR). The following 
parameters were measured, of which normal values are age-related. Autonomic 
dysfunction was present if two or more of the following four tests were abnormal: 
1. Respiratory RR interval variation: The shortest RR interval during inspiration 
and the longest RR interval during expiration were measured over two 
minutes.  The Expiratory/Inspiratory (E/I) ratio was calculated: mean RRmax 
(mean)/mean RRmin (mean). 
2. Valsalva: measured the shortest RR interval during Valsalva for 15 seconds 
and longest RR interval within 30s after Valsalva.  The longest/shortest RR 
ratio was then calculated.  
3. Maximum/minimum 30:15 ratio: calculated by measuring the longest RR 
interval between beat 20 and 40, divided by the shortest RR interval 
between beat 5 and 25 after standing up. 
4. Orthostatic dysregulation: The difference in systolic blood pressure (sysBP) 
was measured from sysBP in the supine position to the lowest sysBP within 
three minutes of being in the upright position.  An abnormal result was a 




Table S1: Baseline 24 hour ECG results in study patients, comparing those developing and not 
developing significant arrhythmias over the three years. 
Values expressed as n (%) 
ECG, electrocardiogram




Patients not developing 
arrhythmias (n=11) 
Abnormal 24 hour 
ambulatory ECG 
8/16 (50) 5/6 (83) 3/10 (30) 
Supraventricular tachycardia 2/16 (13) 0/6 (0) 2/10 (20) 
Atrial fibrillation 0/16 (0) 0/6 (0) 0/10 (0) 
Atrial flutter 0/16 (0) 0/6 (0) 0/10 (0) 
Ventricular tachycardia 0/16 (0) 0/6 (0) 0/10 (0) 
Couplet  3/16 (19) 3/6 (50) 0/10 (0) 
Triplet 1/16 (6) 1/6 (17) 0/10 (0) 
Dropped beat 3/16 (19) 2/6 (25) 1/10 (10) 
Pause 1/16 (6) 0/6 (0) 1/10 (10) 
Bradycardia 0/16 (0) 0/6 (0) 0/10 (0) 
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Table S2: Cardiac serum biomarker and CMR outcomes in study participants with abnormal and normal EP tests at baseline  
EP test Variable Abnormal EP test Normal EP test Mean difference 
(95% CI) 
SAE Cardiac serum biomarker 
Hs-TnI (ng/l)  257 (223) (n=3) 25 (54) (n=9) 232 (-307.17, 770.35) 
NT-proBNP (ng/l)  180(158) (n=4) 136 (146) (n=9) 44 (-154, 241) 
CK (iu/l)  230 (214) (n=4) 84 (38) (n=8) 146(-190, 483) 
CMR 
LGE present*  0 (0) (n=2) 3 (50) (n=6) - 
ECV (%)  27 (4) (n=2) 30 (4) (n=6) -3 (-10, 4) 
MPR (%)  2.28 (0.20) (n=2) 2.36 (1.47) (n=6) -0.13 (-2.82, 2.56) 
LVEF (%)  61(3) (n=2) 59 (5) (n=7) 1 (-8, 11) 
LV mass/BSA (g/m2)   37 (6) (n=2) 46 (14) (n=7) -9 (-34, 15) 
Autonomic testing   Cardiac serum biomarker 
Hs-TnI (ng/l)  194 (185) (n=5) 4 (2) (n=8) 190 (-40, 420) 
NT-proBNP (ng/l) 210 (168) (n=6) 86 (86) (n=8) 125 (-53, 303) 
CK (iu/l)  185 (179) (n=6) 82 (41) (n=7) 103 (-50, 256) 
CMR 
LGE present*  1 (33) (n=3) 3 (50) (6) - 
ECV (%)   28 (3) (n=3) 29 (4) (n=6) -2 (-7, 4) 
MPR (%)  1.75 (0.41) (n=3) 2.56 (1.36) (n=6) -0.80 (-2.76, 1.15) 
LVEF (%)  61 (8) (n=3) 59 (4) (n=7) 1(-7, 10) 
LV mass/BSA (g/m2)   39 (6) (n=3) 49(13) (n=7) -10 (-28, 9) 
24 hour ambulatory 
ECG 
Cardiac serum biomarker 
Hs-TnI (ng/l)  119 (174) (n=8) 12 (14) (n=7) 107 (-39, 252) 
NT-proBNP (ng/l) 223 (138) (n=8) 63 (42) (n=8) 164 (47, 281) 
CK (iu/l)  151(178) (n=7) 95 (41) (n=8) 57 (-82, 196) 
CMR 
LGE present*  1 (25) (n=4) 3 (43) (n=7) - 
ECV (%)  31 (2) (n=4) 29 (4) (n=7) 1 (-4, 6) 
4 
 
MPR (%) 1.70 (0.52) (n=4) 2.36 (1.31) (n=7) -0.66 (-2.24, 0.92) 
LVEF (%)  62 (2) (n=5) 59(4) (n=7) 4 (-3, 1) 
LV mass/BSA (g/m2)  43(9) (n=5) 45(14) (n=7) -2 (-18, 1) 
Mean (SD) values unless stated otherwise  
*n, % 
BSA, body surface area; CK, creatine kinase; CI, confidence interval; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; ECV, extracellular-
volume fraction; EP, electrophysiology; Hs-TnI, high-sensitivity troponin; ILR, implantable loop recorder; LGE, late gadolinium enhancement; LV, left 
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